



This is only an advertisement for information purposes and is not a prospectus announcement.

Please scan this QR Code  
To view the Prospectus



# SUNREST LIFESCIENCE LIMITED

Corporate Identification Number: U74999GJ2017PLC099606

Our Company was originally incorporated as "Sunrest Lifescience Private Limited" as a Private Limited Company under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated October 30, 2017, issued by the Registrar of Companies, Ahmedabad, Gujarat. Subsequently, our Company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of our Company held on March 09, 2023 and the name of our Company was changed to "Sunrest Lifescience Limited". A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated March 21, 2023 was issued by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of our Company is U74999GJ2017PLC099606. For details of change in registered office of our Company, please refer to chapter titled "Our History and Certain Other Corporate Matters" beginning on page number 114 of the Prospectus.

**Registered Office:** FF-41, Ajay Tenament-6, Near Canal Near Ritanagar Bus Stand, Vastral Road, Ahmedabad-382415, Gujarat, India  
**Website:** <http://www.sunrestlifescience.com>; **Tel No:** +91-079 - 29918245; **Email Id:** [info@sunrestlifescience.com](mailto:info@sunrestlifescience.com);  
**Company Secretary and Compliance Officer:** Ms. Nishi Shah

**PROMOTERS OF OUR COMPANY: MR. NIKHILKUMAR Y THAKKAR, MR. AMITBHAI SHAMBHUL THAKKAR, MR. BHAGYESH KIRITBHAI PAREKH AND MR. BHARATKUMAR V THAKKAR**

## THE ISSUE

**INITIAL PUBLIC ISSUE OF UPTO 12,91,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF SUNREST LIFESCIENCE LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 1084.608 LAKHS ("THE ISSUE"), OF WHICH 65.600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE AGGREGATING TO ₹ 55.104 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 12,25,600 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE AGGREGATING TO ₹ 1029.504 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30.09 % AND 28.56% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.**

**THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10.00 AND THE ISSUE PRICE IS ₹ 84/-  
THE ISSUE PRICE IS 8.4 TIMES OF THE FACE VALUE**

**THIS ISSUE IS BEING MADE IN TERMS OF CHAPTER IX OF THE SECURITIES EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED ("SEBI (ICDR) REGULATIONS"). IN TERMS OF RULE 19(2)(b)(i) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED, THIS IS AN ISSUE FOR AT LEAST 25% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THIS ISSUE IS A FIXED PRICE ISSUE AND ALLOCATION IN THE NET ISSUE TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 253 OF THE SEBI (ICDR) REGULATIONS. FOR FURTHER DETAILS, PLEASE REFER CHAPTER TITLED "ISSUE PROCEDURE" BEGINNING ON PAGE 221 OF THE PROSPECTUS.**

**FIXED PRICE ISSUE AT RS.84/- PER EQUITY SHARE**

<b>MINIMUM LOT SIZE</b>	<b>1,600 EQUITY SHARES FOR RETAIL INDIVIDUAL INVESTORS</b>
	<b>1,600 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER FOR OTHER INVESTORS INCLUDING NII/QIB CATEGORY</b>

## RISK TO INVESTORS:

- Our Equity Shares have never been publicly traded, and may experience price and volume fluctuations following the completion of the Issue. Further, our Equity Shares may not result in an active or liquid market and the price of our Equity Shares may be volatile and you may be unable to sell your Equity Shares at or above the Issue Price or at all.
- The average cost of acquisition of Equity Shares by our Promoters is as follows:

Sr. No.	Name of the Promoters	Average cost of Acquisition (in Rs.)
I.	Bharatkumar V Thakkar	0.00
II.	Bhagyesh Kiritbhai Parekh	0.00
III.	Amitbhai Shambhul Thakkar	0.044
IV.	Nikhilkumar Y Thakkar	0.044

Investors are required to refer section Investors are required to refer section titled "Risk Factors" on page no. 23 of the Prospectus.

ISSUE

**OPENS ON: TUESDAY, NOVEMBER 07, 2023**

**CLOSES ON: THURSDAY, NOVEMBER 09, 2023**

<b>ASBA*</b>	Simple, Safe, Smart way of Application- Make use of it!!!!	*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For further details check section on ASBA below.	Mandatory in Public Issues from January 01, 2016 No cheque will be accepted.
<b>UPI</b> <small>UNIFIED PAYMENTS INTERFACE</small>	UPI now available in ASBA for individual UPI Applicants, whose application size are up to ₹ 5.00 lakh, applying through Registered Brokers, DPs & RTAs. Applicant to ensure PAN is updated in Bank Account being blocked by ASBA Bank. List of Bank supporting UPI is also available in SEBI at <a href="http://www.sebi.gov.in">www.sebi.gov.in</a> .		

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by (i) Retail Individual Investors applying in the Retail Portion, and (ii) Individual Non-Institutional Investors applying with an application size of up to ₹ 500,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" beginning on page no 221 of the Prospectus. The process is also available on the website of Association of Investment Bankers of India ("AIBI"), the website of NSE and in the General Information Document. ASBA Application forms can be downloaded from the website of the Stock Exchange and can be obtained from the list of banks that is available on the website of Securities and Exchange Board of India ("SEBI") at [www.sebi.gov.in](http://www.sebi.gov.in).

Investors applying using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecog=nisedFpi=yes&intmid=40> and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecog=nisedFpi=yes&intmid=34>) respectively, as updated from time to time. Axis Bank Limited has been appointed as Sponsor Bank for the Issue. For Issue related grievance investors may contact: Mark Corporate Advisors Private Limited, Mr. Niraj Kothari, Tel: +91 22 2612 3208, E-mail: [smeipo@markcorporateadvisors.com](mailto:smeipo@markcorporateadvisors.com). For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and Mail Id: [ipc.upi@npci.org.in](mailto:ipc.upi@npci.org.in); AXIS BANK LIMITED at Tel: +91 96196 98042 and Email: [fort.branchhead@axisbank.com](mailto:fort.branchhead@axisbank.com); and the Registrar to the Issue at Skyline Financial Services Private Limited, Tel: +91 1126812682 and E-Mail: [Viren@Skylinerta.com](mailto:Viren@Skylinerta.com). All Investors shall participate in this Issue only through the ASBA process. For details in this regard, specific attention is invited to "Issue Procedure" on page no 221 of the Prospectus. Applicants should ensure that DP ID, PAN, UPI ID (if applicable, in case of investor applying through UPI mechanism) and the Client ID are correctly filled in the Application Form. The DP ID, PAN and Client ID provided in the Application Form should match with the DP ID and Client ID available in the Depository database, otherwise, the Application Form is liable to be rejected. Applicant should ensure that the beneficiary account provided in the Application Form is active. Applicants should note that on the basis of the PAN, DP ID and Client ID as provided in the Application Form, the Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for any correspondences related to the Issue. Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants sole risk.

**PROPOSED LISTING:** The Equity Shares offered through this Prospectus are proposed to be listed on the SME Platform of the National Stock Exchange of India Limited ("NSE EMERGE"). In terms of the Chapter IX of the SEBI ICDR Regulations, as amended from time to time, our Company has received in-principle approval letter dated September 20, 2023 from NSE for using its name in this Offer document for listing our shares on the NSE EMERGE. For the purpose of this Issue, the Designated Stock Exchange will be National Stock Exchange of India Limited.

**DISCLAIMER CLAUSE OF SEBI:** Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Draft Prospectus was not filed with SEBI and the SEBI shall not issue any observation on Offer Document. Hence, there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "Disclaimer Clause of SEBI" on page 200 of the Prospectus.

**DISCLAIMER CLAUSE OF NSE:** It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the 'Disclaimer Clause of NSE on page no. 200 of the Prospectus.

**GENERAL RISKS:** Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their own investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page number 23 of this Prospectus.

**BASIS OF ISSUE PRICE:** The Issue Price is determined by the Company in consultation with the Lead Manager. The financial data presented in chapter "Basis for Issue Price" on page 81 of the Prospectus is based on Company's Restated Financial Statements. Investors should also refer to the chapter titled "Risk Factors" and "Restated Financial Statements" on page 23 and 138 respectively of the Prospectus. The Audit Committees at a meeting recommended the Price noting that the Price is justified based on quantitative factors and key financial and operational performance indicators ("KPIs") disclosed in "Basis for Issue Price" section vis-à-vis the WACA of primary issuances/secondary transactions disclosed in the "Basis for Issue Price" section.

## PRECAUTIONARY NOTICE TO INVESTORS:

Investors are advised to read the Prospectus including the Risk Factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risk factors mentioned on page no. 23. Specific attention of the investors is invited to that any News/Advertisements/ SMS/ Messages/ Articles and Videos, if any, being circulated in the digital media and/or print media, speculating about the investment opportunity in our Company's issue and about equity shares of our Company being available at premium and/or discount to the Issue price ("Message") during the issue period is and/ or will not and/ or has not been issued by our Company or any of our Directors, Key Managerial Personnel, Promoters, Promoter Group or Group Companies. any such message in circulation is misleading & fraudulent advertisement and issued by a third party to sabotage the IPO. Our Company or any of our Directors, Key Managerial Personnel, Promoters, Promoter Group or Group Companies and the intermediaries are not involved in any manner whatsoever.

**ADDITIONAL INFORMATION AS REQUIRED UNDER SECTION 30 OF THE COMPANIES ACT, 2013:** Main Objects as per MoA of our Company: For information on the main objects of our Company, see "History and Certain Corporate Matters" on page 114 of the Prospectus and Clause III(A) of the Memorandum of Association of our Company. The MoA is a material document for inspection in relation to the Issue.

**Liability of Members:** The Liability of members of Company is Limited.

**Amount of Share Capital of Our Company and Capital Structure:** For details of the share capital and capital structure of the Company see "Capital Structure" on page 55 of the Prospectus.

**Name of the Signatories to the MOA of the Company and the number of Equity Shares held by them:**

Original signatories			Current promoters		
Name of Promoters	Face Value (Rs.)	No. of Shares	Name of Promoters	Face Value (Rs.)	No. of Shares
Alpeshkumar Vardhihal Thakkar	10	3,333	Amitbhai Shambhul Thakkar	10	7,49,000
Amitbhai Shambhul Thakkar	10	3,334	Nikhilkumar Y Thakkar	10	7,50,000
Nikhilkumar Yashvantlal Thakkar	10	3,333	Bhagyesh Kiritbhai Parekh	10	6,75,000
-	-	-	Bharatkumar V Thakkar	10	6,75,000

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
<b>Mark Corporate Advisors Private Limited</b> CIN - U67190MH2008PTC181996 404/1, The Summit Business Bay, Sant Janabai Road (Service Lane), Off W. E. Highway, Vile Parle (East), Mumbai-400 057. Maharashtra, India Tel. No.: +91 22 2612 3208 Email ID: <a href="mailto:smeipo@markcorporateadvisors.com">smeipo@markcorporateadvisors.com</a> Investor Grievance Email ID: <a href="mailto:investorgrievance@markcorporateadvisors.com">investorgrievance@markcorporateadvisors.com</a> Contact Person: Mr. Niraj Kothari Website: <a href="http://www.markcorporateadvisors.com">www.markcorporateadvisors.com</a> ; SEBI Regn. No.: INM000012128	<b>Skyline Financial Services Private Limited</b> CIN - U74899DL1995PTC071324 D-153/ A, First Floor, Okhla Industrial Area, Phase - I, New Delhi - 110020 Telephone - +91 1126812682 E-mail id: <a href="mailto:Viren@Skylinerta.com">Viren@Skylinerta.com</a> Investor Grievance Email: <a href="mailto:grievances@skylinerta.com">grievances@skylinerta.com</a> Contact person: Mr. Subhash Dhingreja Website: <a href="http://www.skylinerta.com/">http://www.skylinerta.com/</a> ; SEBI Regn. No.: INR000003241	<b>Sunrest Lifescience Limited</b> Ms. Nishi B Shah Company Secretary and Compliance Officer FF-41, Ajay Tenament-6, Near Canal Near Ritanagar Bus Stand, Vastral Road, Ahmedabad-382415, Gujarat, India Telephone: +91-079 - 29918245, E-mail: <a href="mailto:cs@sunrestlifescience.com/">cs@sunrestlifescience.com/</a>  Investors can contact the Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, credit of allotted shares in the respective beneficiary account, etc.

**AVAILABILITY OF PROSPECTUS:** Investors should note that Investment in Equity Shares involves a degree of risk and investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus shall be available at the website of Stock Exchange at [www.nseindia.com](http://www.nseindia.com), the website of Lead Manager at [www.markcorporateadvisors.com](http://www.markcorporateadvisors.com) and the website of the Issuer Company at <http://www.sunrestlifescience.com> and the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in).

**AVAILABILITY OF APPLICATION FORMS:** Application Form can be obtained from the Registered Office of Company, Sunrest Lifesciences Limited, Tel. No: +91-079 - 29918245; Office of Lead Manager: Mark Corporate Advisors Private Limited, Email: [smeipo@markcorporateadvisors.com](mailto:smeipo@markcorporateadvisors.com), Tel No.: +91 22 2612 3208; Self Certified Syndicate Banks; Registered Brokers; Designated RTA Locations and Designated CDP Locations for participating in the Issue. Application Forms will also be available on the websites of the Stock Exchange and at all the Designated Branches of SCSBs, the list of which is available on the websites of the Stock Exchange and SEBI.

**CREDIT RATING:** As this is an Offer of Equity Shares, there is no credit rating for this offer.

**DEBENTURE TRUSTEES:** This is an Offer of equity shares, hence appointment of debenture trustee is not required.

**IPO GRADING:** Since the Offer is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, there is no requirement of appointing an IPO Grading agency.

**BASIS FOR ISSUE PRICE:** The Issue Price is determined by our Company in consultation with the Lead Manager. The financial data presented in the section "Basis for Issue Price" on page 81 of the Prospectus, are based on our Company's restated financial statements. Investors should also refer to the sections titled "Risk Factors" and "Financial Information" on pages 23 and 138, respectively, to get a more informed view before making the investment decision.

**BANKER TO ISSUE & SPONSOR BANK:** Axis Bank Limited

**All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Prospectus dated October 28, 2023**

**For Sunrest Lifesciences Limited**  
On behalf of the Board of Directors  
Sd/-  
**Nikhilkumar Y Thakkar**  
Managing Director  
DIN: 07962800

Date: **November 03, 2023**  
Place: **Ahmedabad**

Sunrest Lifesciences Limited is proposing, subject to market conditions and other considerations, public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad. The Prospectus is available on the website of the Lead Manager at [www.markcorporateadvisors.com](http://www.markcorporateadvisors.com) the website of the NSE i.e. [www.nseindia.com](http://www.nseindia.com) and website of the Issuer Company at <http://www.sunrestlifescience.com>.

Investor should read the Prospectus carefully, including the Risk Factors on page 23 of the Prospectus before making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be issued and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be issued or sold, and Application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Size : 16x50

Sunjet Com.